RMTI Quote, Financials, Valuation and Earnings

Axogen has a net margin of 5.88% compared to Rockwell Medical's net margin of -3.82%. Rockwell Medical's return on equity of -5.32% beat Axogen's return on equity of -14.85%.

Rockwell Medical has a consensus price target of --, signalling upside risk potential of 212.5%. On the other hand Axogen has an analysts' consensus of -- which suggests that it could grow by 15.13%. Given that Rockwell Medical has higher upside potential than Axogen, analysts believe Rockwell Medical is more attractive than Axogen.

Rockwell Medical has a beta of 1.379, which suggesting that the stock is 37.916% more volatile than S&P 500. In comparison Axogen has a beta of 1.063, suggesting its more volatile than the S&P 500 by 6.272%.

Rockwell Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.

Rockwell Medical quarterly revenues are $28.3M, which are smaller than Axogen quarterly revenues of $48.6M. Rockwell Medical's net income of $1.7M is higher than Axogen's net income of -$1.9M. Notably, Rockwell Medical's price-to-earnings ratio is -- while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical is 0.64x versus 3.76x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.

Cormedix has a net margin of 5.88% compared to Rockwell Medical's net margin of -24.24%. Rockwell Medical's return on equity of -5.32% beat Cormedix's return on equity of -72.96%.

Rockwell Medical has a consensus price target of --, signalling upside risk potential of 212.5%. On the other hand Cormedix has an analysts' consensus of -- which suggests that it could grow by 89.62%. Given that Rockwell Medical has higher upside potential than Cormedix, analysts believe Rockwell Medical is more attractive than Cormedix.

Rockwell Medical has a beta of 1.379, which suggesting that the stock is 37.916% more volatile than S&P 500. In comparison Cormedix has a beta of 1.543, suggesting its more volatile than the S&P 500 by 54.28%.

Rockwell Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

Rockwell Medical quarterly revenues are $28.3M, which are larger than Cormedix quarterly revenues of $11.5M. Rockwell Medical's net income of $1.7M is higher than Cormedix's net income of -$2.8M. Notably, Rockwell Medical's price-to-earnings ratio is -- while Cormedix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical is 0.64x versus -- for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 5.88% compared to Rockwell Medical's net margin of 8.37%. Rockwell Medical's return on equity of -5.32% beat Merit Medical Systems's return on equity of 9.56%.

Rockwell Medical has a consensus price target of --, signalling upside risk potential of 212.5%. On the other hand Merit Medical Systems has an analysts' consensus of $113.20 which suggests that it could grow by 15.3%. Given that Rockwell Medical has higher upside potential than Merit Medical Systems, analysts believe Rockwell Medical is more attractive than Merit Medical Systems.

Rockwell Medical has a beta of 1.379, which suggesting that the stock is 37.916% more volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.844, suggesting its less volatile than the S&P 500 by 15.557%.

Rockwell Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical pays -- of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend.

Rockwell Medical quarterly revenues are $28.3M, which are smaller than Merit Medical Systems quarterly revenues of $339.8M. Rockwell Medical's net income of $1.7M is lower than Merit Medical Systems's net income of $28.4M. Notably, Rockwell Medical's price-to-earnings ratio is -- while Merit Medical Systems's PE ratio is 47.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical is 0.64x versus 4.35x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 5.88% compared to Rockwell Medical's net margin of -49.65%. Rockwell Medical's return on equity of -5.32% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Rockwell Medical has a consensus price target of --, signalling upside risk potential of 212.5%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Rockwell Medical, analysts believe NovaBay Pharmaceuticals is more attractive than Rockwell Medical.

Rockwell Medical has a beta of 1.379, which suggesting that the stock is 37.916% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Rockwell Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Rockwell Medical pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Rockwell Medical quarterly revenues are $28.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Rockwell Medical's net income of $1.7M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Rockwell Medical's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Rockwell Medical is 0.64x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.